The prognostic and predictive value of vascular response parameters measured by dynamic contrast-enhanced-CT, -MRI and -US in patients with metastatic renal cell carcinoma receiving sunitinib

ObjectivesTo identify dynamic contrast-enhanced (DCE) imaging parameters from MRI, CT and US that are prognostic and predictive in patients with metastatic renal cell cancer (mRCC) receiving sunitinib.MethodsThirty-four patients were monitored by DCE imaging on day 0 and 14 of the first course of sunitinib treatment. Additional scans were performed with DCE-US only (day 7 or 28 and 2 weeks after the treatment break). Perfusion parameters that demonstrated a significant correlation (Spearman p < 0.05) with progression-free survival (PFS) and overall survival (OS) were investigated using Cox proportional hazard models/ratios (HR) and Kaplan-Meier survival analysis.ResultsA higher baseline and day 14 value for Ktrans (DCE-MRI) and a lower pre-treatment vascular heterogeneity (DCE-US) were significantly associated with a longer PFS (HR, 0.62, 0.37 and 5.5, respectively). A larger per cent decrease in blood volume on day 14 (DCE-US) predicted a longer OS (HR, 1.45). We did not find significant correlations between any of the DCE-CT parameters and PFS/OS, unless a cut-off analysis was used.ConclusionsDCE-MRI, -CT and ultrasound produce complementary parameters that reflect the prognosis of patients receiving sunitinib for mRCC. Blood volume measured by DCE-US was the only parameter whose change during early anti-angiogenic therapy predicted for OS and PFS.Key Points• DCE-CT, -MRI and ultrasound are complementary modalities for monitoring anti-angiogenic therapy.• The change in blood volume measured by DCE-US was predictive of OS/PFS.• Baseline vascular heterogeneity by DCE-US has the strongest prognostic value for PFS.

[1]  Stuart A. Taylor,et al.  Imaging biomarker roadmap for cancer studies , 2016, Nature Reviews Clinical Oncology.

[2]  J O Barentsz,et al.  Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. , 2009, Cancer treatment reviews.

[3]  C. M. L. V. Herpena,et al.  Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study , 2017 .

[4]  V. Vilgrain,et al.  Evaluation with DCE-US of antiangiogenic treatments in 539 patients allowing the selection of one surrogate marker correlated to overall survival. , 2012 .

[5]  I. Pedrosa,et al.  Evaluation of Treatment Response in Patients with Metastatic Renal Cell Carcinoma: Role of State-of-the-Art Cross-Sectional Imaging , 2012, Current Urology Reports.

[6]  Meng-Xing Tang,et al.  Physical Phenomena Affecting Quantitative Imaging of Ultrasound Contrast Agent , 2009 .

[7]  Y. Kono,et al.  Dynamic contrast enhanced ultrasound assessment of the vascular effects of novel therapeutics in early stage trials , 2012, European Radiology.

[8]  Gilles Chatellier,et al.  Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. , 2010, Radiology.

[9]  Gregory Karczmar,et al.  Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  L S Fournier,et al.  Radiological evaluation of response to treatment: application to metastatic renal cancers receiving anti-angiogenic treatment. , 2014, Diagnostic and interventional imaging.

[11]  Raffi Karshafian,et al.  Quantifying Vascular Heterogeneity Using Microbubble Disruption-Replenishment Kinetics in Patients With Renal Cell Cancer , 2014, Investigative radiology.

[12]  I. Tannock,et al.  Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC). , 2015 .

[13]  M. Okada,et al.  [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[14]  B. Johansen,et al.  Anti‐angiogenic therapy affects the relationship between tumor vascular structure and function: A correlation study between micro–computed tomography angiography and dynamic contrast enhanced MRI , 2016, Magnetic resonance in medicine.

[15]  A. Kiss,et al.  Reprint of: Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature. , 2014, Urologic oncology.

[16]  M. Jeong,et al.  Pretreatment assessment of tumor enhancement on contrast‐enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy , 2010, Cancer.

[17]  V. Goh,et al.  Perfusion CT imaging of treatment response in oncology. , 2015, European journal of radiology.

[18]  G. Parker,et al.  DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents , 2007, British Journal of Cancer.

[19]  V. Goh,et al.  Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. , 2011, Radiology.

[20]  A. Jackson,et al.  Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies , 2012, Nature Reviews Clinical Oncology.

[21]  Ross Williams,et al.  Improved flow measurement using microbubble contrast agents and disruption-replenishment: clinical application to tumour monitoring. , 2011, Ultrasound in medicine & biology.

[22]  S. L. Bridal,et al.  Clinical relevance of contrast-enhanced ultrasound in monitoring anti-angiogenic therapy of cancer: current status and perspectives. , 2010, Critical reviews in oncology/hematology.

[23]  C. Howard,et al.  Metastatic renal cell carcinoma imaging evaluation in the era of anti-angiogenic therapies , 2016, Abdominal Radiology.

[24]  Linda Chami,et al.  Dynamic contrast-enhanced ultrasonography (DCE-US) with quantification of tumor perfusion: a new diagnostic tool to evaluate the early effects of antiangiogenic treatment , 2007, European radiology.

[25]  J. Haanen,et al.  Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib , 2010, British Journal of Cancer.

[26]  Ting-Yim Lee.  Functional CT: physiological models , 2002 .

[27]  A. Kiss,et al.  Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature. , 2014, Urologic oncology.

[28]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  D. McDonald,et al.  Rapid vascular regrowth in tumors after reversal of VEGF inhibition. , 2006, The Journal of clinical investigation.

[30]  Vicky Goh,et al.  CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies , 2010, Cancer biology & therapy.

[31]  Wolfgang A Weber,et al.  Assessing Tumor Response to Therapy , 2009, Journal of Nuclear Medicine.

[32]  Peter N. Burns,et al.  Dynamic microbubble contrast-enhanced US to measure tumor response to targeted therapy: a proposed clinical protocol with results from renal cell carcinoma patients receiving antiangiogenic therapy. , 2011, Radiology.

[33]  J. Gore,et al.  Correlation Between Estimates of Tumor Perfusion From Microbubble Contrast‐Enhanced Sonography and Dynamic Contrast‐Enhanced Magnetic Resonance Imaging , 2006, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[34]  P. Nathan,et al.  Imaging techniques as predictive and prognostic biomarkers in renal cell carcinoma , 2013, Therapeutic advances in medical oncology.

[35]  A R Jayaweera,et al.  Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. , 1998, Circulation.

[36]  K. Flaherty,et al.  Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma , 2008, Cancer biology & therapy.

[37]  R. Karshafian,et al.  Quantification of flow using ultrasound and microbubbles: a disruption replenishment model based on physical principles. , 2009, Ultrasound in medicine & biology.

[38]  Steven P Sourbron,et al.  On the scope and interpretation of the Tofts models for DCE‐MRI , 2011, Magnetic resonance in medicine.

[39]  M. Kohli,et al.  Response criteria in oncologic imaging: review of traditional and new criteria. , 2013, Radiographics : a review publication of the Radiological Society of North America, Inc.

[40]  Shetal N Shah,et al.  Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. , 2010, AJR. American journal of roentgenology.

[41]  M. Knopp,et al.  Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.

[42]  S. Koscielny,et al.  Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography , 2010, Clinical Cancer Research.